Breast Cancer

In the largest study of its kind, breast cancer survivors were not found to have a greater mortality risk due to heart disease than the general population.

The findings could lead to broader access to cancer drug Z-endoxifen for further clinical study

New drug shows promising signs of delaying the development of existing breast and lung cancers. .

A novel chimera targets the growth factors responsible for certain types of breast cancer.

Triple-negative and HER2-positive breast cancers may be unlikely to develop lymph node metastases.

Over the years, a number of landmark clinical studies on the management of breast cancer have been published, sharpening how patients are treated today.

Overweight patients with BRCA mutations may be more likely to develop breast cancer.

Top news of the week from Specialty Pharmacy Times.

Over the years, a number of landmark clinical studies on the management of breast cancer have been published, sharping how patients are treated today.

Breast cancer treatments may affect men differently than women.

Breast cancer survivors and insurance companies could gain a better understanding of mortality risk with a new model.

Olaparib (Lynparza) double objective response rate compared with other breast cancer drugs.

Officials with the FDA have approved ibalizumab-uiyk (Trogarzo, TaiMed Biologics), the first antiretroviral medication for adults with HIV who cannot be successfully treated with other therapies.

A new direct-to-consumer test analyzes saliva for 3 BRCA variants that may elevate the risk of various types of cancer.

A new direct-to-consumer test analyzes saliva for 3 BRCA variants that may elevate the risk of various types of cancer.

Top news of the week from Specialty Pharmacy Times.

The FDA previously approved abemaciclib for use in combination with fulvestrant in women with HR+/HER2- advanced breast cancer with disease progression following endocrine therapy.

Newly-discovered gene mutations could double the risk of breast cancer.

Three genes may increase the risk of breast and ovarian cancers in patients with BRCA mutations.

Patients with a high risk of recurrent breast cancer may not receive chemotherapy.

The Maraba virus combined with an immune checkpoint inhibitor increased triple-negative breast cancer survival in mice.

Olaparib (Lynparza) is indicated to treat HER2-negative metastatic breast cancer with BRCA mutations.

Advancing biomarker research may help determine which patients with non-invasive breast cancer will develop invasive disease.

Conflicting breast cancer treatment guidelines can leave many decisions to the discretion of the provider.

Providing information about breast cancer surgery via an online tool may help patients feel more informed about their treatment options.